South Korea reports over 500,000 COVID-19 cases
South Korea's total confirmed cases exceeded 500,000 on 10 December 2021, with 7,022 new infections reported, including 2,800 in Seoul and 2,030 in Gyeonggi Province.
Herald section
Health
The latest health reporting from The Belfast Herald.
Centers for Disease Control and Prevention recommends that people as young as 16 years receive a booster dose of the COVID-19 vaccine.
The Centers for Disease Control and Prevention recommends that people as young as 16 years receive a booster dose of the COVID-19 vaccine. This comes after the FDA authorized the usage of the Pfizer–BioNTech COVID-19 vaccine as a booster dose for people in that age group.
Denmark extends school holidays and closes nightlife over rising infections
The Danish government announced early school closures and nightlife shutdowns from 10 December due to a surge in COVID-19 cases, including omicron variant detections.
India's Serum Institute announces that it will halve the production of its COVID-19 vaccine because it has no new orders for the vaccine
India's Serum Institute announces that it will halve the production of its COVID-19 vaccine because it has no new orders for the vaccine.
South Korea reports 7,175 new COVID-19 cases, total reaches 489,484
South Korea recorded 7,175 new cases in 24 hours, raising the national total to 489,484, with 80% of infections in greater Seoul and 35% in those aged 60 and above.
Northern Ireland reports its first cases of the SARS-CoV-2 Omicron variant in two people from the same household in the greater Belfast area and a third unrelated person
Northern Ireland reports its first cases of the SARS-CoV-2 Omicron variant in two people from the same household in the greater Belfast area and a third unrelated person.
70% of Missouri adults have received first COVID-19 vaccine dose
Approximately 70.1% of adults in Missouri have received at least one dose of the COVID-19 vaccine, according to state health officials.
EMA and ECDC approve mixing of COVID-19 vaccines
The EMA and ECDC have approved the use of different COVID-19 vaccines for initial and booster doses, citing evidence of strong immune responses from heterologous schedules.